Program
Clascoterone
Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.
Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cassiopea SpA | 70 open or running | phase 3since Nov 17, 2015 | Nov 17, 2015 | none ahead |
| Sun Pharmaceutical Industries | 61 open or running | phase 4since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| 3SBio | 32 open or running | phase 3since Apr 30, 2024 | Apr 30, 2024 | Aug 7, 2028phase 3 · NCT07457294 |
| Intrepid Therapeutics | 30 open or running | phase 2since Jun 27, 2012 | Jun 27, 2012 | none ahead |
Also a collaborator on its studies: canfield-scientific-inc and icon-clinical-research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2012First study: phase 2 study in Acne VulgarisNew to Intrepid TherapeuticsIntrepid Therapeutics · NCT01631474 · 363 enrolled · United States
- Apr 11, 2013Phase 2 study in Acne VulgarisIntrepid Therapeutics · NCT01831960 · 42 enrolled · United States
- Oct 7, 2014Phase 2 study in AlopeciaIntrepid Therapeutics · NCT02279823 · 95 enrolled · United States
- Nov 17, 2015Cassiopea SpA's first studies: 2 phase 3 studies in Acne VulgarisNew to Cassiopea SpACassiopea SpA · NCT02608476, NCT02608450
- Feb 10, 2016Phase 3 study in Acne VulgarisCassiopea SpA · NCT02682264 · 609 enrolled · United States, Bulgaria, Georgia and more
- Mar 22, 2016Phase 2 study in Acne VulgarisCassiopea SpA · NCT02720627 · 27 enrolled · United States, Poland
- Jun 18, 2018Phase 1 study in Healthy VolunteersCassiopea SpA · NCT03665194 · 32 enrolled · United Kingdom
- Jun 6, 20232 phase 3 studies in AlopeciaCassiopea SpA · NCT05914805, NCT05910450
- Mar 11, 2024Sun Pharmaceutical Industries's first studies: 2 phase 4 studies in Acne VulgarisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT06336629, NCT06336603
- Apr 30, 20243SBio's first study: phase 3 study in Acne VulgarisNew to 3SBio3SBio · NCT06403501 · 692 planned · China
- May 10, 20244 phase 4 studies in Acne VulgarisSun Pharmaceutical Industries · NCT06425900, NCT06415305, NCT06415292 and 1 more
- May 31, 2024Phase 1 study in Acne Vulgaris3SBio · NCT06454708 · 12 enrolled · China
- Feb 26, 2026Phase 3 study in Acne Vulgaris3SBio · NCT07457294 · 692 planned
Ahead
- Aug 7, 2028Primary completion: phase 3 study in Acne Vulgaris3SBio · NCT07457294
TargetBeta
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07457294Acne Vulgaris | 3 | Not yet recruiting | 3SBio | Aug 7, 2028 | 692 |
| NCT06454708Acne Vulgaris · China | 1 | Completed | 3SBio | Aug 12, 2024 | 12 |
| NCT06425900Acne Vulgaris · United States | 4 | Active, not recruiting | Sun Pharmaceutical Industries | Mar 2026 | 10 |
| NCT06415305Acne Vulgaris · United States | 4 | Completed | Sun Pharmaceutical Industries | Apr 17, 2024 | 10 |
| NCT06415292Acne Vulgaris · United States | 4 | Completed | Sun Pharmaceutical Industries | Dec 16, 2023 | 50 |
| NCT06415279Acne Vulgaris · United States | 4 | Completed | Sun Pharmaceutical Industries | Feb 12, 2025 | 40 |
| NCT06403501Acne Vulgaris · China | 3 | Recruiting | 3SBio | Oct 2026 | 692 |
| NCT06336629Acne Vulgaris · United States | 4 | Completed | Sun Pharmaceutical Industries | Jul 10, 2024 | 10 |
| NCT06336603Acne Vulgaris · United States | 4 | Completed | Sun Pharmaceutical Industries | Oct 29, 2024 | 20 |
| NCT05914805Alopecia · United States, Germany, Poland | 3 | Completed | Cassiopea SpA | Jul 16, 2025 | 762 |
| NCT05910450Alopecia · United States, Georgia | 3 | Completed | Cassiopea SpA | Jan 26, 2026 | 703 |
| NCT03665194Healthy Volunteers · United Kingdom | 1 | Completed | Cassiopea SpA | Sep 12, 2018 | 32 |
| NCT02720627Acne Vulgaris · United States, Poland | 2 | Completed | Cassiopea SpA | Mar 21, 2018 | 27 |
| NCT02682264Acne Vulgaris · United States, Bulgaria, Georgia and more | 3 | Completed | Cassiopea SpA | Aug 31, 2018 | 609 |
| NCT02608476Acne Vulgaris · United States, Bulgaria, Georgia and more | 3 | Completed | Cassiopea SpA | Feb 21, 2018 | 732 |
| NCT02608450Acne Vulgaris · United States, Georgia, Ukraine | 3 | Completed | Cassiopea SpA | Apr 11, 2018 | 708 |
| NCT02279823Alopecia · United States | 2 | Completed | Intrepid Therapeutics | Dec 2015 | 95 |
| NCT01831960Acne Vulgaris · United States | 2 | Completed | Intrepid Therapeutics | Nov 2013 | 42 |
| NCT01631474Acne Vulgaris · United States | 2 | Completed | Intrepid Therapeutics | Feb 2014 | 363 |
How it is read
Names in the registry
- “Winlevi (clascoterone) 1% cream”, 3 entries
- “CB-03-01 cream, 1%”, 3 entries
- “Clascoterone 5% solution”, 2 entries
- “cortexolone 17α-propionate”, 2 entries
- “CB-03-01”, 2 entries
Conditions, from the studies’ own filings
- Acne Vulgaris, 15 studies
- Alopecia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.